Femasys (FEMY) Competitors $0.70 -0.04 (-5.67%) Closing price 04:00 PM EasternExtended Trading$0.63 -0.08 (-10.68%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FEMY vs. SLNO, EDAP, PSTV, GUTS, ZJYL, LUNG, QTI, DXR, ICCM, and MDAIShould you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Soleno Therapeutics (SLNO), EDAP TMS (EDAP), Plus Therapeutics (PSTV), Fractyl Health (GUTS), Jin Medical International (ZJYL), Pulmonx (LUNG), QT Imaging (QTI), Daxor (DXR), IceCure Medical (ICCM), and Spectral AI (MDAI). These companies are all part of the "medical equipment" industry. Femasys vs. Its Competitors Soleno Therapeutics EDAP TMS Plus Therapeutics Fractyl Health Jin Medical International Pulmonx QT Imaging Daxor IceCure Medical Spectral AI Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation. Is SLNO or FEMY more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,113.72%. Soleno Therapeutics' return on equity of -73.74% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -73.74% -56.67% Femasys -1,113.72%-713.74%-152.60% Does the media prefer SLNO or FEMY? In the previous week, Soleno Therapeutics had 10 more articles in the media than Femasys. MarketBeat recorded 12 mentions for Soleno Therapeutics and 2 mentions for Femasys. Femasys' average media sentiment score of 0.48 beat Soleno Therapeutics' score of 0.38 indicating that Femasys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Femasys 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend SLNO or FEMY? Soleno Therapeutics presently has a consensus target price of $115.92, indicating a potential upside of 77.05%. Femasys has a consensus target price of $7.33, indicating a potential upside of 943.00%. Given Femasys' higher possible upside, analysts plainly believe Femasys is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.93Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable earnings & valuation, SLNO or FEMY? Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.14-15.81Femasys$1.63M14.05-$18.82M-$0.86-0.82 Which has more risk and volatility, SLNO or FEMY? Soleno Therapeutics has a beta of -2.75, meaning that its stock price is 375% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.64, meaning that its stock price is 364% less volatile than the S&P 500. Do institutionals & insiders believe in SLNO or FEMY? 97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by insiders. Comparatively, 11.5% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummarySoleno Therapeutics and Femasys tied by winning 8 of the 16 factors compared between the two stocks. Get Femasys News Delivered to You Automatically Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FEMY vs. The Competition Export to ExcelMetricFemasysMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.91M$3.42B$6.09B$10.54BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-0.8222.5884.6327.10Price / Sales14.05483.04606.05131.34Price / CashN/A46.9737.8662.13Price / Book7.0310.4112.246.58Net Income-$18.82M-$52.47M$3.32B$276.75M7 Day Performance14.79%2.30%0.76%0.91%1 Month Performance97.11%14.45%8.03%4.18%1 Year Performance-42.37%12.90%71.13%35.42% Femasys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FEMYFemasys2.8585 of 5 stars$0.70-5.7%$7.33+943.0%-39.4%$22.91M$1.63M-0.8230News CoverageHigh Trading VolumeSLNOSoleno Therapeutics4.1448 of 5 stars$64.27+0.8%$115.92+80.4%+24.8%$3.39BN/A-15.5230EDAPEDAP TMS3.0535 of 5 stars$2.09+1.0%$8.50+306.7%-11.4%$77.40M$69.18M-3.43230Short Interest ↓PSTVPlus Therapeutics3.205 of 5 stars$0.68-2.9%$8.00+1,081.5%-57.1%$69.22M$5.82M-0.3020Short Interest ↑Gap DownGUTSFractyl Health2.6402 of 5 stars$1.34flat$6.90+414.9%-48.6%$67.39M$90K-0.65102Short Interest ↑ZJYLJin Medical InternationalN/A$0.41-3.1%N/A-85.4%$66.08M$23.50M0.00245Short Interest ↑Gap DownLUNGPulmonx3.9063 of 5 stars$1.59+0.6%$7.66+382.0%-76.9%$64.38M$83.79M-1.11250QTIQT ImagingN/A$2.25+0.9%N/A+237.5%$61.05M$4.00M0.00N/ADXRDaxor3.8032 of 5 stars$12.88+2.1%$25.00+94.1%+42.2%$60.99MN/A0.0037Positive NewsICCMIceCure Medical2.5857 of 5 stars$0.84-3.1%$2.64+212.3%+52.8%$59.85M$3.29M-5.2760MDAISpectral AI2.1455 of 5 stars$2.21-0.9%$3.50+58.4%+90.7%$59.61M$29.58M-3.2083Gap Up Related Companies and Tools Related Companies Soleno Therapeutics Alternatives EDAP TMS Alternatives Plus Therapeutics Alternatives Fractyl Health Alternatives Jin Medical International Alternatives Pulmonx Alternatives QT Imaging Alternatives Daxor Alternatives IceCure Medical Alternatives Spectral AI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FEMY) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
